Top Markets
Coin of the day
Cellectis S.A. Cellectis S.A.

Cellectis S.A.

ALCLS
Rank in Stocks #17130
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and... Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric antigen receptors (CARs) for the specific identification and destruction of cancer cells. Its operations are divided into two principal segments: Therapeutics and Plants. The company's pipeline features several allogeneic CAR T-cell product candidates. These include UCART19, aimed at CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A, developed to treat relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316, targeting renal cell carcinoma; UCART123, for acute myeloid leukemia; and UCART22, addressing B-cell acute lymphoblastic leukemia. Additionally, Cellectis is advancing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. Cellectis has forged significant strategic partnerships and alliances with companies including Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. It also maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc.
Share Price
$3.56
Market Cap
$257.37M
Change (1 day)
5.26%
Change (1 year)
38.35%
Country
FR
Trade Cellectis S.A. (ALCLS)

Category

Stock price history for Cellectis S.A. (ALCLS)
Highest end of day price: $3.46 on 2026-09-01

Lowest end of day price: $17.72 on 2007-02-01
Stock price history of Cellectis S.A. from 2007 to 2026
Annual Stock Price Performance
Year Performance
2026 (TTM) -20.49%
2025 169.48%
2024 -42.86%
2023 40.69%
2022 -74.52%
2021 -70.75%
2020 74.88%
2019 -10.96%
2018 -29.07%
2017 53.46%
2016 -41.97%
2015 106.63%
2014 307.22%
2013 -61.60%
2012 7.76%
2011 -4.53%
2010 -42.92%
2009 103.43%
2008 -44.49%
2007 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$548.15 36.70%
US
$1.03K 45.33%
NL
$153.87 536.09%
US
$122.21 -10.03%
AU
$756.15 7.98%
CH